Apilimod compositions and methods for using same
The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
1. A method for treating a follicular lymphoma in a human subject in need thereof, the method comprising administering a pharmaceutical composition comprising apilimod, or a pharmaceutically acceptable salt thereof, to the subject in a therapeutically effective amount.
2. The method of claim 1 , wherein the pharmaceutical composition is an oral dosage form.
3. The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from a sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, besylate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate.
4. The method of claim 3 , wherein the pharmaceutically acceptable salt is selected from a chloride, mesylate, fumarate, lactate, maleate, pamoate, phosphate, and tartrate.
5. The method of claim 1 , wherein the method comprises administering the apilimod, or pharmaceutically acceptable salt thereof, in combination with at least one additional active agent.
6. The method of claim 5 , wherein the at least one additional active agent is administered in the same dosage form as the apilimod, or in a separate dosage form.
7. The method of claim 5 , wherein the at least one additional active agent is rituximab.
8. The method of claim 1 , wherein the human subject in need is one whose follicular lymphoma is refractory or recurrent.
9. The method of claim 7 , wherein the human subject in need is one whose follicular lymphoma is refractory or recurrent.